News & Updates
Filter by Specialty:
High blood pressure, Scarff Bloom-Richardson grade 3 predict CV events in breast cancer
Pre-existing cardiovascular disease (CVD) and grade 3 Scarff Bloom-Richardson are associated with the occurrence of cardiovascular (CV) events among women with breast cancer, reports a study.
High blood pressure, Scarff Bloom-Richardson grade 3 predict CV events in breast cancer
13 Apr 2022
Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab
Ustekinumab is well tolerated and proves to be effective in the second-line treatment of patients with Crohn’s disease, according to real-world data from the Cross Pennine II study. Furthermore, while clinical remission appears to occur sooner with ustekinumab than with vedolizumab, the two drugs perform comparably at maintaining remission over 12 months.
Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab
12 Apr 2022
Older NSCLC patients with smaller tumours prefer SBRT over lobectomy
Both surgery and use of stereotactic body radiation therapy (SBRT) result in a decrease in the mean tumour size of early-stage nonsmall cell lung cancer (NSCLC), a recent study has shown.
Older NSCLC patients with smaller tumours prefer SBRT over lobectomy
12 Apr 2022
Which signs separate MIS-C from COVID-19, Kawasaki disease, toxic shock syndrome?
Children with multisystem inflammatory syndrome in children (MIS-C) show significantly higher prevalence of cardiac complications, elevated markers of inflammation and cardiac damage, thrombocytopenia, and lymphopenia than do those with COVID-19, Kawasaki disease (KD), and toxic shock syndrome (TSS), reports a study.
